Skip to content
Screener

Bausch + Lomb BLCO OTC — Total revenues

Other product segments

Devices
$524M+11.0%
Branded and Other Generics
$68M+17.2%

Similar metrics at other companies

PBH
PBHInternational OTC Healthcare — Total revenues
$39.5M+6.9%
PBH
PBHNorth American OTC Healthcare — Total revenues
$226.21M+6.4%
Vistra logo
VSTTransferable PTC revenues — Total revenues
$2M0.0%
Intercontinental Exchange logo
ICEOT Cand Other Transactions — Total revenues
$111M+15.6%
Sonida Senior Living logo
SNDAResident revenue — Total revenues
$108.43M+36.8%
Asset Entities logo
ASSTOther revenue — Total revenues
$43K+514%

Other financials

Income statement

See full
Revenue$1.4B+9.1%
Operating income$83.0M+855%
Net income-$14.0M+77.4%
EPS (diluted)-$0.04+77.8%

Balance sheet

See full
Cash & equivalents$378.0M+39.0%
Total debt$5.1B+2.4%
Total equity$6.4B-1.0%
Total assets$13.9B+0.2%

Cash flow

See full
Operating cash flow$153.0M+337%
CapEx$71.0M-20.2%
Free cash flow$82.0M+252%

Valuation

See full
Market cap$5.84B+17.0%
Enterprise value$10.54B+8.9%
P/S1.1×+0.1×

Profitability

See full
Operating margin6.1%+5.3pp
Net margin-3.2%-1.0pp
FCF margin-3.4%0.0pp

Returns & leverage

See full
Return on equity-2.7%-0.7pp
Debt / equity0.8×0.0×
Current ratio1.5×0.0×

Where this comes from

Reported directly by Bausch + Lomb in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Bausch + Lomb’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:17 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001860742-26-000088
(in millions)Vision Care / Three Months Ended June 30, 2026Vision Care / Three Months Ended June 30, 2025Pharmaceuticals / Three Months Ended June 30, 2026Pharmaceuticals / Three Months Ended June 30, 2025Surgical / Three Months Ended June 30, 2026Surgical / Three Months Ended June 30, 2025Total / Three Months Ended June 30, 2026Total / Three Months Ended June 30, 2025
Pharmaceuticals$1$1$299$259$300$260
Devices270258254214524472
OTC497482497482
Branded and Other Generics131055486858
Other revenues3222256
$784$753$354$309$256$216$1,394$1,278
Six Months Ended June 30,
20262025202620252026202520262025

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Bausch + Lomb's OTC — total revenues?
Bausch + Lomb (BLCO) reported OTC — total revenues of $497M in Q2 2026.
How has Bausch + Lomb's OTC — total revenues changed year-over-year?
Bausch + Lomb's OTC — total revenues increased by 3.1% year-over-year, from $482M to $497M.
What is the long-term trend for Bausch + Lomb's OTC — total revenues?
Over 4 years (2021 to 2025), Bausch + Lomb's OTC — total revenues has grown at a 7.1% compound annual growth rate (CAGR), from $1.39B to $1.84B.
What does OTC — total revenues mean?
This metric represents the total gross revenue generated from the sale of over-the-counter ophthalmic and vision care products. It reflects the market demand and commercial performance of consumer-facing eye health solutions that do not require a prescription. Tracking this revenue stream provides insight into the company's brand strength and competitive positioning within the retail consumer health market.

Ask your AI about Bausch + Lomb's otc — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude